Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial

Authors:

Abstract
Objective: This study aimed to apply The Lancet Diabetes & Endocrinology criteria for diagnosing obesity among clinical trial participants and understand participants' characteristics by obesity status. Methods: The criteria were operationalized and applied to baseline data from the Long‐term Effectiveness of the Anti‐obesity medication Phentermine (LEAP) trial (NCT05176626). Excess adiposity, organ and tissue dysfunction, and limitations to daily activities were assessed. We examined differences between participants with “no obesity,” “pre‐clinical obesity,” and “clinical obesity.” Results: Among the 860 participants, 0.8% had no obesity (mean BMI 29.0 kg/m 2 [SD 0.6]), 18.7% had pre‐clinical obesity (mean BMI 35.2 kg/m 2 [SD 3.5]), and 80.5% had clinical obesity (mean BMI 35.9 kg/m 2 [SD 4.3]). Participants with no/pre‐clinical obesity had lower mean SF‐12 mental component scores and greater baseline engagement with weight control strategies compared to those with clinical obesity. Participants with clinical obesity were older and, by definition, had a greater burden of cardiometabolic risk factors. Conclusions: Among clinical trial participants eligible for obesity pharmacotherapy, 19.5% were classified as having no/pre‐clinical obesity using the Lancet criteria. Applying the criteria was complicated in a well‐resourced trial setting, which suggests potential challenges in implementing these guidelines in real‐world practice.
Funding Information
  • National Heart, Lung, and Blood Institute (UH3HL155801)
  • National Heart, Lung, and Blood Institute (U24HL155802)

This publication has 20 references indexed in Scilit: